An active year for Swedish biotech and pharmaceutical companies
The Swedish life science industry is constituted of 1,391 companies within all major sectors – pharma, biotech and medtech. Of these, around 890 are running research and development programs based in Sweden (Tillväxtanalys PM 2016:04).
This report includes 144 Swedish companies actively developing pharmaceutical drugs, of which 67 companies have projects in clinical phase I–III.
This report provides you with an in-depth analysis of the clinical research projects, an overview of the preclinical projects as well as company information, including geographical location, statistics on number of employees and more.
This year’s edition also includes an exclusive list of all clinical and preclinical projects, showcasing the Swedish pipeline compounds, indications therapeutic areas and clinical stage progression stage of development. The list can be found at the end of the report.
Key findings in the 2016 report include:
- In total, there are currently 369 projects in the pipeline, of which 144 are in clinical development.
- Since last year’s report four products were approved for new markets and two market approvals are pending.
- Oncology projects dominate, making up 30% of the clinical pipeline.
- One third of the clinical research projects target an orphan indication, and a record high number of companies were granted orphan designation by EMA and/or FDA in 2015.
- Special highlight on women’s health this year revealed 22 projects in the pipeline.
- Ten new companies were founded in 2015, and twelve companies were listed on the Swedish stock exchange.
The report can be downloaded here: http://swedenbio.se/wp-content/uploads/2016/12/The-Swedish-Drug-Discovery-Development-Pipeline-20161.pdf